UNASSIGNED: The successful treatment of @entity1583 remains challenging. Prognosis is often dismal given the frequency of disease relapse or treatment refractory disease. @entity137 and cytostatic chemotherapy remain mainstream therapeutics for most @entity1583 . However, improved understanding of @entity5 immunobiology is providing appealing anti- @entity5 strategies targeting selected component of immune response. Since approval of rituximab for treating B cell malignancies in 1997, develop of monoclonal antibodies against @entity5 specific surface molecules has driven the development of the emerging field of @entity5 immunotherapy. This strategy of modulating the immune response is taking an increasingly prominent role in the treatment of @entity1583 with several new antibody-based therapeutics becoming available for @entity1 with @entity1778 / @entity706 . In addition, with an increasingly appreciated role for T cell immunity in @entity5 pathogenesis, strategies enhancing T cell activation as well as inhibiting T cell suppression mechanisms are under active development. Therapeutic vaccines to improve efficacy of antigen processing and presentation, agonists for co-stimulatory molecules, adoptive transfer of genetically-modified T cells, as well as agents that suppress negative regulatory pathways for T cell function are all under active clinical investigation. Although most of these studies are in early stages, preliminary data are very promising. Availability of additional immune-based therapeutic options for @entity1 with @entity1583 is anticipated in the near future.

Novel Immunotherapies for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Cytotoxic'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies']
@entity1583 :: (MESH:D019337,Disease) :: ['Hematological Malignancies']
